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Since the diabetic effect of alloxan was discovered in 1943, this 
drug has been used in biomedical research to recapitulate the 
physiology of diabetes in various animal models.45 Alloxan is 
a glucose analog that is specific to glucose transporter 2, which 
is expressed almost exclusively by hepatocytes and pancreatic 
β cells.35,45 When glucose transporter 2 conveys alloxan into the 
cytosol of pancreatic β cells, the toxin reacts with intracellular 
glutathione in a redox reaction, resulting in the formation of re-
active oxygen species that cause β-cell death.22,34,35 After admin-
istration of alloxan, extensive β-cell necrosis is often observed.45 
Some studies show long-term recovery after alloxan-induced 
diabetes, which is suspected to be due to either multiplication 
of surviving β cells or the formation of new β cells from the duct 
epithelium or the exocrine portion of the pancreas.10,32,41,45
The efficacy of alloxan can be unpredictable and is depen-
dent on several factors, including species,34 route of adminis-
tration,22,32 speed of administration,32 and diet.45 Although it 
is widely accepted that alloxan and streptozotocin, another 
diabetogenic agent, affect younger animals to a lesser extent 
than older animals, this belief is based only on a few studies 
in mice.28,48 The only study to cite the age-dependence of al-
loxan in a large animal model was published almost 70 y ago 
in dogs.15,22,32,45 With the variation between species and even 
between subjects of the same species, the possible age-depen-
dent effects of alloxan in large animal models need to be reex-
amined.
In this study, we used the clinically relevant Ossabaw minia-
ture swine (Sus scrofa domestica) model of metabolic syndrome—
the clustering of risk factors including obesity, dyslipidemia, 
glucose intolerance, insulin resistance, and hypertension—to 
determine whether age-conferred protection against the diabetic 
effects of alloxan is present in swine. This study will either con-
tradict the alloxan–age dogma or provide additional evidence 
of the age-dependent effects of alloxan in large animal models.
Materials and Methods
Animals, housing, and diet. All experimental procedures 
involving animals were approved by the IACUC at Indiana 
University School of Medicine, according to recommendations 
outlined by the National Research Council and the American 
Veterinary Medical Association Panel on Euthanasia.3,31 Swine 
were obtained from a closed, SPF breeding colony at Purdue 
University (West Lafayette, IN). This herd has historically tested 
negative for Brucella spp., pseudorabies, vesicular stomatitis 
virus serovars Indiana and New Jersey, Mycoplasma hyopneu-
moniae, porcine reproductive and respiratory syndrome virus, 
porcine parvovirus, swine influenza virus serotypes H1N1 
and H3N2, antibodies to transmissible gastroenteritis virus, 
and Leptospira interrogans serovars (canicola, grippotyphosa, 
hardjo, icterohaemorrhagiae, pomona, and bratislava). All pigs 
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were housed in pairs in 24-ft2 pens under a 12:12-h light:dark 
cycle. Temperature was maintained at 20 to 22 °C throughout 
the study, and humidity was not controlled. After the induc-
tion of diabetes, all swine were immediately placed for 6 mo 
on a hypercaloric atherogenic diet (1000 to 1350 g daily for both 
groups; KT324, Purina Test Diet, Richmond, IN) consisting of 
43% of total caloric intake from fat, 16% from protein, and 41% 
from carbohydrates, similar to previous studies.19 Swine were 
fed once daily to promote gorging behavior to ensure that the 
daily allotment of food was consumed completely. Feed intake 
and blood glucose were measured daily, and body weight was 
monitored weekly. Water was provided without restriction.
Central venous line placement. Swine were restrained in a 
sling and anesthetized with 5% isoflurane in 100% O2 admin-
istered by mask. The unconscious pig was placed in the supine 
position, and a percutaneous needle with a syringe attached 
was inserted into the angle formed by the sternum and clavicle. 
Negative pressure was maintained in the syringe, and when it 
began to fill with dark-red venous blood, the needle was held 
in place and the syringe removed. A guidewire was fed through 
the percutaneous needle, at which point the needle was re-
moved. A central venous catheter was fed over the guidewire, 
which was then removed. The catheter was capped and secured 
to the animal by using nonabsorbable suture. The pig was re-
turned to the sternal position and isoflurane was discontinued, 
allowing the animal to regain consciousness under observation. 
The central line catheter was flushed twice each week, to ensure 
its patency.
Induction of diabetes. To induce diabetes, alloxan (Sigma 
Chemical, St Louis, MO), a pancreatic β-cell toxin, was admin-
istered rapidly intravenously to male and female Ossabaw 
miniature swine (age, 4 to 8 mo). At time of alloxan administra-
tion, swine were placed into 1 of 2 age groups: juvenile (age, 
younger than 6 mo; n = 8) and sexually mature adult52 (age, 6 
mo or older; n = 8). Briefly, alloxan was dissolved in 14 mL of 1 
M NaOH and 20 mL of 0.9% NaCl, for a final volume of 34 mL 
and a pH of 7.4. The alloxan solution was delivered through 
a 0.20-μm sterile filter into a central venous line in the jugular 
vein at an average dose of 140 mg/kg (range, 125 to 175 mg/
kg). All 8 adult swine and 2 juvenile swine each received only 
one dose, whereas the remaining 6 juvenile swine were given 
2 doses over the course of 1 wk, due to lack of hyperglycemic 
response to the first dose. The average first dose was 140 mg/kg 
(range, 75 to 175 mg/kg), and the average second dose was 120 
mg/kg (range, 125 to 150 mg/kg). Different doses were used 
due to interindividual variability in the response to alloxan. To 
protect against possible renal toxicity, pigs were given 250 mL of 
0.9% NaCl through intravenous drip prior to and after alloxan 
dosing. The pigs were fed free-choice and received 24 h of criti-
cal care after diabetes induction, to monitor for hypoglycemic 
shock. Swine received daily insulin glargine (Sanofi, Bridgewa-
ter, NJ) through subcutaneous injection to the flank, according 
to an algorithm previously published by our lab4,8 to maintain 
glycemic control below 300 mg/dL, a clinically relevant hyper-
glycemic level.40 The insulin dose for all pigs was between 0.1 
and 0.6 U/kg and was individually adjusted according to daily 
blood glucose measurements, weekly weight measurements, 
and the presence or absence of lethargic behavior.4 The diabetic 
disease state was allowed to stabilize for 1 wk after alloxan ad-
ministration, at which point all swine were placed on the hyper-
caloric atherogenic diet for 6 mo. Nonalloxanized age-matched 
controls on the same hypercaloric atherogenic diet were used in 
some analyses.
Metabolic phenotyping. Blood for analysis (Antech Diagnos-
tics, Fishers, IN) was collected 1 wk before alloxan dosing and 1 
wk and 6 mo afterward. Homeostasis model assessment-insulin 
resistance (HOMA-IR) is a calculation that takes into account 
fasting glucose and insulin concentrations to assess insulin re-
sistance.55 Increased HOMA-IR values indicate greater insulin 
resistance.26 HOMA-IR was calculated by using the following 
equation: 
 
Blood pressure measurement. From the beginning of the 
study, pigs were acclimated to a low-stress sling42,43 for conduct-
ing intravenous glucose tolerance testing (IVGTT) and blood 
pressure measurement. Blood pressures were measured by us-
ing a tail-cuff sphygmomanometer.42
IVGTT. Insulin treatments were suspended 2 d prior to testing 
to determine endogenous glucose regulation. To assess pancre-
atic β-cell response to glucose, conscious swine that had been 
fasted overnight received 50% glucose solution intravenously 
(dose, 1 g glucose/kg body weight) through the central venous 
line. To obtain fasting glucose concentration, pigs were placed 
in a low-stress restraint sling, and blood samples (3 mL) were 
taken at 10, 5, and 0 min before glucose injection and then at 
5, 10, 20, 30, 40, 50, and 60 min afterward. Blood glucose val-
ues were monitored (Advantage glucose monitor, Accu-Chek, 
Roche, Indianapolis, IN), and plasma insulin values were 
obtained through assays done at the Diabetes Research Core 
(School of Medicine, Indiana University).
Euthanasia. After an overnight fast, swine were anesthetized 
through intramuscular injection of 2.2 mg/kg xylazine and 5.5 
mg/kg tiletamine–zolazepam (Fort Dodge Animal Health, Fort 
Dodge, IA). Swine were intubated, and anesthesia was main-
tained with 2% to 4% isoflurane in 100% O2. The isoflurane level 
was adjusted to maintain anesthesia with stable hemodynamics. 
Pigs were euthanized through cardiectomy.
Immunohistochemistry. Sections from the tail of the pancreas 
were placed in 10% phosphate-buffered formalin for 24 to 48 h 
and then embedded in paraffin. Tissue sections were stained 
(Department of Pathology, School of Medicine, Indiana Uni-
versity) by using guinea pig antiinsulin polyclonal antibody 
(Agilent, Santa Clara, CA) as a marker for β cells. Images were 
captured by using a photomicroscope (model DM 3000, Leica, 
Wetzlar, Germany) and analyzed with ImageJ software.50. Rela-
tive β-cell mass was quantified by calculating the percentage of 
3,3′ diaminobenzidine–stained nuclear area relative to the total 
nuclear area by using the ImmunoRatio ImageJ plugin.
Statistics. Statistical analysis was performed by using Prism 
5.0 (GraphPad San Diego, CA). The Student t test, nonparamet-
ric Kruskal–Wallis one-way ANOVA with Dunn posthoc anal-
ysis, or 2-way ANOVA with Bonferroni posthoc analysis was 
performed. Data are represented as mean ± SEM, and nonpara-
metric data are represented by dot plots expressing the median 
and interquartile range. A P value less than 0.05 was considered 
statistically significant.
Results
Insulin resistance in swine. Because juvenile and adult swine 
had comparable metabolic parameters before alloxan ad-
ministration, they were pooled into the alloxan pretreatment 
group. Although the juvenile swine were significantly (P < 
0.001) younger than the adult swine, both groups exhibited 
comparable weights and BMI measurements after 6 mo on an 
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atherogenic diet. Compared with levels before alloxan admin-
istration, serum triglycerides in adult pigs were elevated both 1 
wk and 6 mo after alloxan. Total cholesterol was elevated in all 
groups after 6 mo on an atherogenic diet. HOMA-IR calculations 
showed that the adult swine at 6 mo after alloxan treatment 
were more insulin resistant than adults before alloxan admin-
istration and compared with juveniles at 6 mo after alloxan 
dosing. To assess kidney function, creatinine and BUN levels 
were measured. Creatinine levels were comparable between 
groups, with untreated controls exhibiting slightly elevated (P 
< 0.05) levels compared with juvenile swine at 1 wk after al-
loxan, whereas adult swine at 1 wk after alloxan administration 
exhibited elevated BUN levels compared with before alloxan (P 
< 0.001) and juvenile levels (P < 0.01) that normalized by 6 mo 
after alloxan dosing. To measure liver function, serum levels 
of AST and ALT were measured and compared with reference 
ranges, and the AST:ALT ratio was calculated. At 6 mo after al-
loxanization, both juvenile and adult swine exhibited elevated 
AST and ALT levels, indicative of liver dysfunction.14,49 In ad-
dition, both groups had increased AST:ALT ratios at 6 mo after 
alloxan treatment, but these were equivalent to the AST:ALT ra-
tio of nonalloxanized high-fat–fed control swine. Furthermore, 
systolic blood pressure and mean arterial pressure were greater 
in adult swine at 6 mo after alloxan administration compared 
with before treatment (Table 1).
Glucose clearance after alloxan treatment in adult compared 
with juvenile swine. Blood glucose at 60 min after intravenous 
administration of a bolus of glucose was assessed at 1 wk 
(Figure 1 A through C) and 6 mo (Figure 1 D through F) after 
alloxan administration. At 1 wk after alloxan treatment, IVGTT 
showed that adult swine had significantly (P < 0.05) higher 
blood glucose measurements at all time points when compared 
with both juvenile swine and all swine before alloxan adminis-
tration (Figure 1 A). This association is reflected in the higher 
baseline fasting glucose level (Figure 1 B) and greater glucose 
AUC (Figure 1 C). This hyperglycemia persisted at 6 mo after 
alloxan administration, with adult swine exhibiting significantly 
(P < 0.05) higher glucose concentrations at most time points dur-
ing glucose challenge compared with juvenile pigs and adult swine 
before alloxan treatment (Figure 1 D), higher (P < 0.05) baseline 
fasting glucose level (Figure 1 E), and a greater (P < 0.05) glucose 
AUC (Figure 1 F). Juvenile swine had a significantly (P < 0.05) 
greater glucose AUC than nonalloxanized swine at 6 mo after 
alloxan administration (Figure 1 F), thus demonstrating a pro-
gression of glucose intolerance in juvenile pigs.
Relationship between age and fasting blood glucose level in 
alloxanized swine. The fasting blood glucose level of swine at 
1 wk after the final alloxan dose was plotted against the age 
at which each pig was alloxanized (Figure 2). This analysis re-
vealed a strong positive correlation between blood glucose level 
and age at the time of alloxan administration, even for compa-
rable doses of alloxan.
Hypoinsulinemia in swine. Serum insulin levels were mea-
sured during IVGTT. At 1 wk after alloxan administration, 
both juvenile and adult swine exhibited lower glucose levels 
than before alloxan administration at all time points except 
t = 0 (Figure 3 A). This finding is reflected in the insulin AUC 
analysis (Figure 3 B). This hypoinsulinemia persists at 6 mo 
after alloxan administration, with juvenile and adult swine 
exhibiting lower insulin levels at several time points when 
compared with untreated, age-matched animals (Figure 3 C). 
Again, juvenile and adult alloxanized swine had smaller insu-
lin AUC than nonalloxanized swine (Figure 3 D). An outlier 
in the juvenile group whose serum insulin concentration was 
5fold greater than the standard deviation was removed from 
this analysis.
Recovery of insulin response. Insulin AUC (Figures 3 B and 
3 D) were used to determine potential recovery from alloxan 
Table 1. Metabolic profiles show hyperlipidemia and insulin resistance in swine 6 mo after consumption of an atherogenic diet
Before alloxan
1 wk after alloxan treatment 6 mo after alloxan treatment Nonalloxanized 
swine fed an athero-
genic dietJuvenile Adult Juvenile Adult
Age (mo) — 4.3 ± 0.2 7.4 ± 0.2b 11.0 ± 0.2b,c 14.0 ± 0.1b,c,d 12.6 ± 1.1b,c
Sex (M/F) 8/8 3/5 5/3 3/5 5/3 4/4
Body weight (kg) 24.9 ± 1.6 22.2 ± 1.0 29.7 ± 1.0 67.8 ± 2.6a,b,c 73.5 ± 2.8a,b,c 91.7 ± 2.6a,b,c,d
BMI (kg/m2) — — — 58.6 ± 2.4 59.4 ± 3.2 69.4 ± 1.3d
Serum TG (mg/dL) 33 ± 16 66 ± 15 82 ± 16a 41 ± 7 211 ± 87a,d 40 ± 5e
Total cholesterol (mg/dL) 91 ± 16 93 ± 5 110 ± 7 500 ± 114a,b,c 988 ± 138a,b,c,d 421 ± 59a,b,c,e
HOMA-IR 2.9 ± 0.4 3.3 ± 0.3 4.6 ± 0.3 2.3 ± 0.3 5.4 ± 1.0a,d 2.7 ± 0.2e
Creatinine (mg/dL) 1.1 ± 0.1 0.9 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.3 ± 0.1b
BUN (mg/dL) 14.7 ± 0.8 16.5 ± 3.1 27.4 ± 3.4a,b 14.9 ± 0.9c 16.9 ± 1.0c 11.9 ± 1.5c
AST (IU/L) 34 ± 2 35 ± 5 37 ± 3 98 ± 19a,b,c 85 ± 11a,b,c 47 ± 7d,e
ALT (IU/L) 54 ± 5 35 ± 4 54 ± 8 62 ± 6b 56 ± 6 34 ± 3a,d,e
AST:ALT 0.66 ± 0.04 0.99 ± 0.06 0.74 ± 0.07 1.68 ± 0.43a 1.73 ± 0.36a 1.48 ± 0.20a
Systolic BP (mm Hg) 131 ± 6 — — 142 ± 10 158 ± 6 138 ± 9
Diastolic BP (mm Hg) 74 ± 5 — — 83 ± 6 88 ± 3a 90 ± 7
MAP (mm Hg) 93 ± 5 — — 103 ± 6 112 ± 3a 106 ± 7
BP, blood pressure; Chol, cholesterol; F, female; HOMA-IR, homeostasis model assessment-insulin resistance; M, male; MAP, mean arterial 
pressure; TG, triglycerides
Data are given as mean ± SEM. Values before alloxan represent pooled juvenile and adult swine.
aP < 0.05 compared with prealloxan swine
bP < 0.05 compared with juvenile swine 1 wk after alloxan
cP < 0.05 compared with adult swine 1 wk after alloxan
dP < 0.05 compared with juvenile swine 6 mo after alloxan
eP < 0.05 compared with adult swine 6 mo after alloxan
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Figure 1. Adult swine exhibited prolonged impaired glucose clearance after intravenous glucose tolerance testing. Blood glucose levels were 
tested for 60 min after a bolus of glucose (1 mg/kg body weight). (A) At 1 wk alloxan administration, adult swine (n = 8) showed a significant 
deficit in glucose clearance at all time points compared with pretreatment controls (n = 16) and juvenile swine (n = 8). (B) The fasting blood 
glucose level was elevated in juvenile animals at baseline and in the adult group at 1 wk after alloxan administration. (C) AUC analysis at 1 
wk after alloxan administration shows impaired glucose clearance in adult alloxanized pigs compared with pretreatment controls and juvenile 
swine. (D) At 6 mo after alloxan administration, adult swine continued to exhibit impaired glucose clearance compared with nonalloxanized 
swine and juvenile swine at most time points. (E) The baseline fasting glucose concentration was elevated in adult swine at 6 mo after alloxan 
administration. (F) At 6 mo after alloxan administration, AUC analysis using the fasting blood glucose concentration as a baseline for each group 
shows impaired glucose clearance in juvenile alloxanized pigs compared with untreated controls; this impaired glucose clearance is exacerbated 
in adult alloxanized animals. *, P < 0.05.
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treatment. Juvenile swine exhibited an approximately 2.5fold 
increase in peripheral insulin levels from 1 wk to 6 mo after al-
loxan dosing (Figure 3 E). In contrast, peripheral insulin levels 
in adult swine remained constant between 1 wk and 6 mo after 
alloxan administration (Figure 3 E).
Pancreatic β-cell area. Immunohistochemical analysis of pan-
creatic tissue from juvenile (Figure 4 A) and adult (Figure 4 B) 
swine showed that pancreatic β-cell area at 6 mo after alloxan 
administration is comparable between juvenile and adult swine 
(Figure 4 C). This value is lower than for nonalloxanized, high-
fat–fed swine, whose pancreatic β-cell mass was calculated pre-
viously to be approximately 7.5%.4
Discussion
In this study, we show that alloxan-treated juvenile swine had 
a blunted response to the drug and did not have the severe dia-
betic effects that developed in adult swine given alloxan. Swine 
that received alloxan regardless of age exhibited decreased pan-
creatic β cell mass (Figure 4) and reduced peripheral plasma 
insulin after a bolus of glucose (Figure 3). However, only the 
juvenile swine exhibited recovery of the insulin response, which 
we defined as the recovery or partial recovery of peripheral in-
sulin levels, at 6 mo after alloxan treatment (Figure 3 E). Juve-
nile and adult alloxanized swine developed comparable risk 
factors for metabolic syndrome, with adult swine exhibiting 
an elevated HOMA-IR (Table 1). Although alloxanized swine 
exhibited elevated ALT and AST levels, they did not exhibit 
critical levels of renal toxicity or hepatoxicity, as indicated by 
their BUN, creatinine, and AST and ALT levels (Table 1), simi-
lar to previous studies.19,42 In addition, fasting blood glucose 
was higher and significantly correlated with age of swine at 
1 wk after alloxanization, even though the dosages of alloxan 
were comparable (Figure 2), and glucose clearance was more 
impaired in the adult swine as well (Figure 1). Taken together, 
these results show that fasting glucose and glucose clearance is 
more impaired in Ossabaw miniature swine that receive alloxan 
as adults than as juveniles and that juvenile swine can recover 
(at least partially) from alloxan treatment.
Pancreatic β cell mass and peripheral plasma insulin were not 
statistically different between the juvenile and adult alloxanized 
swine, even though adult swine exhibited greater hyperglyce-
mia, both fasting and after a glucose challenge. Superficially, this 
result seems to be a paradox, but it can be explained partly by the 
increased peripheral resistance, as calculated by the HOMA-IR, 
in the adult swine.27,38 Under normal physiologic conditions, 
insulin resistance is counteracted by increased insulin secretion 
through β-cell compensation.1 However, the decreased β-cell 
mass due to alloxan treatment of adult swine was accompanied 
by a decreased functional compensation to increasing insulin 
secretion. Consequently, comparable levels of circulating insulin 
would have less of an effect on glucose clearance in the insulin-
resistant adult swine as compared with juvenile swine.
Hyperglycemia-induced secondary insulin resistance is a 
well-documented phenomenon in type 1 diabetic humans36,58 
and in animal models, including swine.18,30,37,42,44,46,47 In a previous 
study, our lab determined that the dramatic decrease in insulin 
sensitivity observed in alloxan-induced diabetic Yucatan swine 
is almost solely due to hyperglycemia.42 This hyperglycemia-
induced insulin resistance is at least partially due to the down-
regulation of glucose transfer type 4 in skeletal muscle by high 
circulating glucose levels.37 The initial hyperglycemic event af-
ter alloxan administration causes the adult swine to become 
more insulin-resistant and thus partially explains why glucose 
clearance at 6 mo after alloxan treatment was more impaired in 
adult pigs than juvenile swine (Figure 1 D–F), even though pe-
ripheral insulin levels (Figure 3 C and D) and pancreatic β-cell 
mass (Figure 4) were comparable between these 2 groups. The 
initial differential effects of alloxan in juvenile compared with 
adult swine contribute to the greater hyperglycemia exhibited 
in adult swine.
The liver plays a vital role in glucose metabolism and may have 
contributed to the differential effects seen in the alloxanized ju-
venile pigs compared with treated adult swine. Insulin secreted 
from the pancreas travels through the portal vein to the liver, 
which binds 60% of the insulin delivered.57 The remaining insulin 
then goes into the peripheral circulation, where it binds to insu-
lin-sensitive tissues, such as skeletal muscle and adipose. How-
ever, hepatic insulin binding doubles in streptozotocin-induced 
diabetes.16 The inverse relationship between circulating insulin 
levels and hepatic insulin binding16 may affect insulin circula-
tion in the alloxanized pigs. Perhaps more insulin was secreted 
in juvenile pigs, but much of the insulin was bound by the liver, 
thereby resulting in greater insulin-mediated glucose uptake by 
the liver and lower fasting glucose compared with these param-
eters in adult pigs. Portal vein insulin levels or c-peptide levels 
are needed to provide direct evidence for this possibility.
Several studies have shown that creatinine increases pro-
gressively with time in alloxanized animals, signaling kidney 
dysfunction.2,54,56 However, at 6 mo after alloxan treatment, cre-
atinine and BUN levels in our treated adult and juvenile pigs 
were comparable to those before treatment and in the nonallox-
anized controls, and the AST:ALT ratio was comparable to that 
of nonalloxanized controls. These results indicate little kidney 
damage and no additional liver damage due to the drug.
Spontaneous recovery from streptozotocin- and alloxan-in-
duced diabetes has been well-documented11,32,41,45 and occurs 
through several potential mechanisms. A recent study in mice 
showed that islet δ cells can be converted into β cells, an ability 
that is lost in adulthood.11 Other hypotheses involve the pro-
liferation of surviving β cells,10,11,32,45 reprogramming of islet α 
cells into β cells,11,13 and conversion of duct epithelial cells to β 
cells.10,32,45 Our study is the first to show recovery from alloxan-
induced diabetes in a large animal model. However, although 
the present study revealed that peripheral insulin levels can 
recover in juvenile swine, we did not delve into the mechanisms 
that drive this recovery. Future studies should focus on nonβ 
islet cell reprogramming in swine of different ages.
Figure 2. Correlation of fasting blood glucose level with age at alloxan 
administration. The fasting blood glucose concentration at 1 wk after 
alloxan administration is significantly positively correlated to the age 
of swine at time of alloxan administration (black). The dose of alloxan, 
however, is not correlated to age (red) and is not significantly different 
between groups. In animals given 2 doses of alloxan, the average of 
the doses was plotted.
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Swine do not reach developmental maturity until 6 mo of 
age.7,25,39,52 In the current study, although the 2 experimental groups 
were only about 3 mo different in age, developmentally this span 
was the difference between juvenile and adulthood.25,39,52 In ad-
dition to the blunted acute (1 wk) β-cell destruction by alloxan in 
juvenile pigs, they showed greater relative recovery of glucose tol-
erance and peripheral insulin responses at 6 mo after alloxan than 
did the adult pigs. This outcome speaks to the immense sensitivity 
of alloxan to animal age and the more robust resistance of juvenile 
pig β cells to alloxan.
The juvenile group contained 3 castrated males and 5 females, 
whereas the adult group contained 5 castrated males and 3 fe-
males (Table 1). The nonalloxanized control group contained 
4 of each sex (Table 1). These differences in the numbers of 
animals of each sex comprising each group could potentially 
affect metabolic parameters, but the differences were not statisti-
cally significant. The effect of sex on weight gain varies among 
Figure 3. Hypoinsulinemia in juvenile and adult swine at 6 mo after alloxanization. (A) Peripheral insulin during intravenous glucose toler-
ance testing was significantly lower in juvenile (n = 7) and adult (n = 8) swine compared with prealloxan controls (n = 16) at 1 wk after alloxan 
administration. (B) AUC analysis reveals comparable hypoinsulinemia in both the juvenile and adult alloxan-treated swine at 1 wk after alloxan 
administration. (C) At 6 mo after alloxan administration, juvenile and adult swine still exhibited hypoinsulinemia at several time points com-
pared with nonalloxanized, age-matched controls (n = 8). (D) AUC analysis revealed comparable hypoinsulinemia in both juvenile and adult 
alloxanized swine 6 mo after alloxan administration. (E) The fold change in peripheral insulin from 1 wk to 6 mo after alloxan was greater in 
juvenile than adult swine. *, P < 0.05 compared with prealloxan or nonalloxanized controls.
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studies, depending on the diet and breed of pig.12,17 In Large 
White × Landrace pigs, intact boars were larger than females, 
whereas the weights of castrated males were comparable to 
those of females.17 Female swine reliably exhibit elevated serum 
cholesterol,5,6,12,33 but the effects of sex on triglyceride levels and 
insulin resistance are less predictable.6,12,33 Of note, the BUN, 
creatinine, ALT, and AST are comparable between male and fe-
male swine.6,33 In our study, even though the adult swine group 
contained more males than females, all of these swine exhibited 
greatly elevated serum triglycerides, cholesterol, and HOMA-IR 
(Table 1). If sex did affect the metabolic profile, then correcting 
for this effect would only make our results more robust.
Furthermore, the vasoprotective effects of estrogen in the cir-
culation have been well documented,21,29,53 as have the harmful 
effects of testosterone.23,53 However, the sex-associated differ-
ences in our study might not be that simplistic, given that fe-
male Yucatan swine have similar serum testosterone levels as 
castrated males9 and that intact female dogs have comparable 
estradiol concentrations as neutered males.24 Although we did 
not measure serum estrogen levels in the current study, the liter-
ature supports the hypothesis that females and castrated males 
from various species have a similar sex hormone profiles.
The current study is the first since 1949 to investigate whether 
the effects of alloxan are dependent on age in large animals. Be-
cause the effects of alloxan can vary widely, different species at 
different stages of maturity need to be tested. Alloxan is widely 
used to elicit diabetes in animal models and characterizing re-
sponses to alloxan will enable researchers to predict whether 
the drug will have the desired effects in their particular model. 
Studies examining how the diabetic effects of alloxan are depen-
dent on age in different species are of the utmost importance, 
given that different animal species and even different breeds 
within a species react differently. For example, pigs require a 
higher dose of alloxan to develop a similar diabetic state as in 
rats, dogs, and rabbits.34,51 Clearly, alloxan has very different 
effects based on the physiology of the species and breed. There-
fore, a single study in one species is not adequate to make a 
sweeping generalization regarding the age of an animal on a 
drug’s effectiveness. The field of diabetic animal models needs 
additional studies both to verify Creutzfeldt’s 1949 findings and 
to determine whether this effect is typical among commonly 
used animal models of diabetes.
In the current study, we show that alloxan more efficaciously 
elicited acute and sustained hyperglycemia when administered 
to adult swine compared with juvenile swine. This result sup-
ports the 70-y-old dogma15 that the diabetic effects of alloxan are 
dependent on age, at least in dogs and minipigs. Future studies 
need to examine other laboratory animal species to determine 
the ubiquity of this age dependence. These studies should focus 
on several ages to create a dose–response curve for frequently 
used animal models. Our current study provides an important 
step in clarifying the effects of a widely used yet relatively un-
predictable drug, thereby enabling researchers to better choose 
the animal species and stage of maturation that are best for their 
study design. This information can save researchers time and 
money and may reduce the number of research animals used.
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Figure 4. Change in β-cell mass in young and adult alloxanized swine. 
Immunohistochemical staining of insulin in pancreas from (A) juve-
nile and (B) adult swine revealed that, at 6 mo after alloxan admin-
istration, both juvenile and adult swine had a lower β-cell mass than 
nonalloxanized controls (in which the insulin-stained area is approxi-
mately 7.5%4). However, (C) β-cell mass did not differ significantly 
between alloxan-treated juvenile and adult swine.
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